Scleroderma in children and adolescents.
The scleroderma disorders remain challenging conditions in pediatric rheumatology to understand pathologically and indeed for which to provide care. It is clear that much progress is being made in the clinical approach to understanding this group of group of disorders. It seems likely that the different lesions of LS may represent unique immunopathogenic mechanisms or perhaps reflect unique genetic or other characteristics of the patients themselves. To take advantage of the revolution in therapies now occurring in rheumatology it is critical that controlled clinical trials are developed with appropriate agreed upon outcome measures for both localized and systemic disease.
Murray
Kevin J
KJ
Department of Rheumatology, Princess Margaret Hospital for Children, GPO Box D184, Perth, WA 6008, Australia. jmangharam@hotmail.com
Laxer
Ronald M
RM
D000293:Adolescent; D000974:Antibodies, Antinuclear / Q000032:analysis; D002648:Child; D003937:Diagnosis, Differential; D004935:Esophageal Diseases / Q000150:complications; D006801:Humans; D008171:Lung Diseases / Q000150:complications; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D011928:Raynaud Disease / Q000150:complications; D012594:Scleroderma, Localized / Q000145:classification / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D012595:Scleroderma, Systemic / Q000150:complications / Q000175:diagnosis / Q000276:immunology / Q000628:therapy
D000974:Antibodies, Antinuclear